Fungal infections are becoming common among critically ill patients, as our patient population is increasingly complex and more frequently immunosuppressed. Traditional curricula often focus on antibacterial agents rather than antifungals, leaving antifungal agents shrouded in a sense of mystery. Antifungals actually aren't that tricky though, as there is a very limited number of them.
-
The IBCC chapter is located 👉 here.
- The podcast & comments are below.
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
Josh is the creator of PulmCrit.org. He is an associate professor of Pulmonary and Critical Care Medicine at the University of Vermont.
Latest posts by Josh Farkas (see all)
- IBCC chapter – Disseminated Intravascular Coagulation (DIC) - January 18, 2021
- PulmCrit- RCTs don't justify using convalescent plasma or antibody cocktails - January 14, 2021
- PulmCrit – Six RCTs to answer one question: what is the role of tocilizumab in COVID-19? - January 12, 2021
Hey Josh
Well covered as usual..
Just a curious doubt but had faced a situation once.
If we get a candida auris uti, which we decide as significant and need to treat, what will be the treatment of choice?
Small correction–you are correct that there isn’t an IV formulation of itraconazole but there is an IV formulation of posaconazole.
Thanks for you work on this site. Always a good read and review of topics and literature
Loved the podcast as always! I did notice one typo though, Amphoterrible typically causes a type I (distal) RTA (not type IV).